Breast cancer P2 Poziotinib info from 2015 SABCS. In light of the ESMO presentation 3 weeks away, I think this abstract is pretty interesting. As you know, I've been scratching my head in figuring out what PFS they are expecting. The abstract indicates they are looking for PFS of 4.5 months as opposed to Standard of Care of 3.3 months. And I have to apologize to Dr Raj. A year or so ago at a CC he was saying that if this trial was successful they would seek AA in Korea. Well, this abstract says they could. On the other hand he was also speculating that maybe that possibility exists in the US but the board correctly pointed out that they couldn't do that based on how the Korean study is set up. Anyhows, here's the abstract.
I am looking forward to the 'Proffered paper'at ESMO, that's for sure. As you pointed out, a Proffered Paper is